Association of serum beta-hCG and urine albumin-creatinine ratio with hypertensive disorders during pregnancy
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20231764Keywords:
Hypertension, Pregnancy, Urine albumin-creatinine ratio, Beta-hCGAbstract
Background: Preeclampsia with or without severe symptoms, chronic hypertension with or without superimposed pre-eclampsia/eclampsia, gestational hypertension, HELLP syndrome, or eclampsia all pose a significant risk of morbidity for both the mother and the unborn child. The aim of this study was to investigate if the albumin-to-creatinine ratio in urine spots and the serum beta-hCG level correlate with the hypertensive illness of pregnancy.”
Method: “The current inquiry was conducted during the months of October 2020 and August 2022 at the obstetrics and gynaecology department of Subharti medical college in Meerut, Uttar Pradesh. The study was not open to women who were more than 20 weeks pregnant, had gestational diabetes mellitus, had more than one pregnancy, had chronic hypertension, chronic renal disease, chronic liver disease, cardiac disease, systemic lupus erythematosus, or haematological illnesses. We measured the levels of serum beta hCG and the urine albumin-creatinine ratio, and we compared them between the groups.”
Results: After ensuring that each participant had given their informed permission, the trial comprised a total of 200 patients. In the hypertensive group of the participants in the study, 31% were between the ages of 21 and 35, and 29% were less than 20 years old. With increased beta hCG and UACR, there was a higher incidence of hypertensive retinopathy, acute renal failure, DIC, and PPH among the patients, as well as the poorest fetal outcomes. (p<0.05)
Conclusions: The presence of a substantial relationship between hypertensive diseases and raised levels of beta-hCG during pregnancy, as well as a greater ratio of urine albumin to creatinine. There is a considerable increase in the incidence of fetal growth retardation, preterm, and mortality occurring within the uterus among mothers who have higher levels of beta-hCG and urine ACR.
Metrics
References
Spiro L, Scemons D. Management of Chronic and Gestational Hypertension of Pregnancy: A Guide for Primary Care Nurse Practitioners. Open Nurs J. 2018;12:180-3.
Holm L, Stucke-Brander T, Wagner S, Sandager P, Schlütter J, Lindahl C et al. Automated blood pressure self-measurement station compared to office blood pressure measurement for first trimester screening of pre-eclampsia. Health Informatics J. 2019;25(4):1815-24.
Fisher SC, Van Zutphen AR, Werler MM, Romitti PA, Cunniff C, Browne ML. Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study. Birth defects Res. 2018;110(19):1433-42.
Lo J, Mission J, Caughey A. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013;25:124-32.
Wolde Z, Segni H, Woldie M. Hypertensive disorders of pregnancy in jimma university specialized hospital. Ethiop J Health Sci. 2011;21(3):147-54.
Von Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83-102.
Brown MA, Mackenzie C, Dunsmuir W, Roberts L, Ikin K, Matthews J et al. Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG An Int J Obstet Gynaecol. 2007;114(8):984-93.
Delić R, Stefanović M. Optimal laboratory panel for predicting preeclampsia. J Matern Fetal Neonatal Med. 2010;23(1):96-102.
Doğru HY, Yücel N, Pelit FÇ, Bolat G. The importance and evaluation of mean platelet volume on the severity of preeclampsia. Perinat J. 2011;19(3):108-13.
Nina M, B. NR. Uric Acid Is as Important as Proteinuria in Identifying Fetal Risk in Women With Gestational Hypertension. Hypertension. 2005;46(6):1263-9.
Abdelaziz A, Maher MA, Sayyed TM, Bazeed MF, Mohamed NS. Early pregnancy screening for hypertensive disorders in women without a-priori high risk. Ultrasound Obstet Gynecol. 2012;40(4):398-405.
Montagnana M, Trenti T, Aloe R, Cervellin G, Lippi G. Human chorionic gonadotropin in pregnancy diagnostics. Clin Chim Acta. 2011;412(17-18):1515-20.
Betz D, Fane K. Human chorionic gonadotropin. In: StatPearls. StatPearls Publishing. 2021.
Evans TRJ, Kudo M, Finn RS, Han K-H, Cheng A-L, Ikeda M et al. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019;121(3):218-21.
Singh R, Bhalla K, Nanda S, Gupta A, Mehra S. Correlation of spot urinary protein: Creatinine ratio and quantitative proteinuria in pediatric patients with nephrotic syndrome. J Fam Med Prim care. 2019;8(7):2343-6.
Ellam TJ. Albumin:Creatinine Ratio-A Flawed Measure? The Merits of Estimated Albuminuria Reporting. Nephron Clin Pract. 2011;118(4):c324-30.
Poon LC, Magee LA, Verlohren S, Shennan A, von Dadelszen P, Sheiner E et al. A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia. Int J Gynecol Obstet. 2021;154(S1):3-31.
Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ. Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring. J Clin Med. 2019;8(10).
Huppertz B. Placental Origins of Preeclampsia. Hypertension. 2008;51(4):970-5.
Aouache R, Biquard L, Vaiman D, Miralles F. Oxidative Stress in Preeclampsia and Placental Diseases. Int J Mol Sci. 2018;19(5).
Wang R, Chen L, Wang X, Liu Y. Association between serum beta-human chorionic gonadotropin and inflammation, oxidative stress in pregnancy-induced hypertension. Microvasc Res. 2021;135:104130.
Rathore N, Khajuria R, Jaggi R. β-hCG levels in second trimester as a predictor of gestational hypertension and preeclampsia. Int J Reprod Contraception, Obstet Gynecol. 2022;11(2):433-7.
Chadha A, Tayade S. Urinary Protein-to-Creatinine Ratio: An Indicator of Adverse Clinical Outcomes in Preeclampsia With Proteinuria. Cureus. 2022;14(3):e23341.
Zhang X, Huangfu Z, Shi F, Xiao Z. Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:1-9.
Kumari AMV. Association between maternal serum beta human chorionic gonadotropin levels and hypertensive disorders of pregnancy. Int J Reprod Contraception, Obstet Gynecol. 2020;9:3157.
Singhal S, Tyagi S, Maheshwari B, Mustafa I. Role of serum beta human chorionic gonadotropin at 13-20 weeks of gestation as a predictor of hypertensive disorders of pregnancy. Int J Clin Obstet Gynaecol. 2020;4(4):219-22.
Murmu S, Dwivedi J. Second-Trimester Maternal Serum Beta-Human Chorionic Gonadotropin and Lipid Profile as a Predictor of Gestational Hypertension, Preeclampsia, and Eclampsia: A Prospective Observational Study. Int J Appl basic Med Res. 2020;10(1):49-53.
Upadhyay A, Dayal M. Screening for preeclampsia by urine albumin to creatinine ratio. New Indian J OBGYN. 2018;4(2):117-20.
Lorzadeh N, Kazemirad S. The effects of fetal gender on serum human chorionic gonadotropin and testosterone in normotensive and preeclamptic pregnancies. J Pregnancy. 2012;2012:874290.
Devi LT, Nimonkar AR. Spot urinary albumin creatinine ratio as a predictor of preeclampsia and dilemma in clinical interpretation. Int J Reprod Contraception Obstet Gynecol. 2018;7:4086.
Mazhari F, Varun N. Prediction of hypertensive disorders in pregnancy by estimation of maternal serum beta hCG levels in the mid-trimester (13-20 weeks) of pregnancy. Int J Biomed Res. 2018;9(10):354-7.
Sachan R, Patel ML, Sachan P, Shyam R, Verma P, Dheeman S. Diagnostic accuracy of spot albumin creatinine ratio and its association with fetomaternal outcome in preeclampsia and eclampsia. Niger Med J. 2017;58(2):58-62.
Amin S V., Illipilla S, Hebbar S, Rai L, Kumar P, Pai M V. Quantifying Proteinuria in Hypertensive Disorders of Pregnancy. Int J Hypertens. 2014;14:1-10.
Kaur G, Jain V, Mehta S, Himani S. Prediction of PIH by Maternal Serum Beta hCG Levels in the Second Trimester (13-20 Weeks) of Pregnancy. J Obstet Gynaecol India. 2012;62(1):32-4.